146 related articles for article (PubMed ID: 24942396)
21. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Stergiopoulos K; Brown DL
JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
[TBL] [Abstract][Full Text] [Related]
22. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
[TBL] [Abstract][Full Text] [Related]
23. VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.
Puehringer H; Loreth RM; Klose G; Schreyer B; Krugluger W; Schneider B; Oberkanins C
Eur J Clin Pharmacol; 2010 Jun; 66(6):591-8. PubMed ID: 20376629
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
van Schie RM; Babajeff AM; Schalekamp T; Wessels JA; le Cessie S; de Boer A; van der Meer FJ; van Meegen E; Verhoef TI; Rosendaal FR; Maitland-van der Zee AH;
J Thromb Haemost; 2012 May; 10(5):767-72. PubMed ID: 22409277
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients.
Verde Z; Santiago C; Valle B; Fernández-Santander A; Bandrés F; Calvo E; Ruiz JR; Lucía A; Gallego FG
Thromb Haemost; 2009 Mar; 101(3):591-3. PubMed ID: 19277427
[No Abstract] [Full Text] [Related]
26. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
27. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
28. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study.
van Schie RM; el Khedr N; Verhoef TI; Teichert M; Stricker BH; Hofman A; Buhre PN; Wessels JA; Schalekamp T; le Cessie S; van der Meer FJ; Rosendaal FR; de Boer A; Maitland-van der Zee AH; Visser LE
Pharmacogenomics; 2012 Aug; 13(11):1239-45. PubMed ID: 22920394
[TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M
Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
[TBL] [Abstract][Full Text] [Related]
30. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
van Schie RM; Wadelius MI; Kamali F; Daly AK; Manolopoulos VG; de Boer A; Barallon R; Verhoef TI; Kirchheiner J; Haschke-Becher E; Briz M; Rosendaal FR; Redekop WK; Pirmohamed M; Maitland van der Zee AH
Pharmacogenomics; 2009 Oct; 10(10):1687-95. PubMed ID: 19842940
[TBL] [Abstract][Full Text] [Related]
31. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
32. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.
Verstuyft C; Delavenne X; Rousseau A; Robert A; Tod M; Diquet B; Lebot M; Jaillon P; Becquemont L
Clin Pharmacokinet; 2012 Jan; 51(1):41-53. PubMed ID: 22149257
[TBL] [Abstract][Full Text] [Related]
33. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
34. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
[TBL] [Abstract][Full Text] [Related]
35. Warfarin, genes, and the (health care) environment.
Kazi DS; Hlatky MA
JAMA Intern Med; 2014 Aug; 174(8):1338-9. PubMed ID: 24934523
[No Abstract] [Full Text] [Related]
36. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
37. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
[TBL] [Abstract][Full Text] [Related]
38. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
[TBL] [Abstract][Full Text] [Related]
39. The value of pharmacogenetic testing.
Pocinki AG
JAMA Intern Med; 2015 Feb; 175(2):314. PubMed ID: 25642672
[No Abstract] [Full Text] [Related]
40. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
